B+
Bull case
20%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
PROK
ProKidneyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-21
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+49.2
Score
AI commentary
Primary-source tone is constructive after the enrollment milestone, but the company is low coverage and recent news and social data are unavailable. Analyst revisions, options skew, short interest, and employee sentiment are also unavailable; the thesis is therefore cautious monitoring rather than high-conviction momentum.
RankAlpha Sentiment Codex - 2026-08-21
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-10eventPROACT 1 accelerated-approval enrollment milestoneHigh impact
ProKidney reported completion of enrollment for the accelerated-approval efficacy analysis, with eGFR-slope topline results anticipated in Q2 2027 [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-10].
2026-08-20catalystRecent director open-market sellingHigh impact
Director Brian Pereira reported open-market sales totaling approximately $952,000 across August 18–20, 2026, creating a near-term sentiment and supply overhang [#SEC-FORM4-2026-08-20].
2026-12-31catalystFull PROACT 1 enrollment completionHigh impact
The company remains on track to complete approximately 470-patient enrollment in the second half of 2026 for the confirmatory analysis [#SEC-8K-2026-08-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-21 • Updated nightlySource: Internal modelMethodology